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Abstract: The miR-320a regulates a number of genes involved in various physiological processes. 
In particular, it has been reported as a tumor suppressor in several types of human cancers and 
involved in osteoporotic fracture and osteoblast function. Hence, the role of miR-320a has been 
evaluated in tumor cells and in primary cells in a separated context, but its effect has never been 
explored in a comparative manner. The present study aims to evaluate the cellular effects of 
miR-320a on human osteosarcoma cell lines (MG-63 and U2OS) compared to that on primary 
human osteoblasts (hOBs). miR-320a was either overexpressed or inhibited in all cell lines, and cell 
proliferation and viability were analyzed. Additionally, the effects of miR-320a on matrix 
mineralization, alkaline phosphatase activity, and oxidative stress were also evaluated in order to 
assess osteoblast functionality. In osteosarcoma cells, miR-320a overexpression reduced cell 
viability and proliferation, while in hOB cell viability was not affected and proliferation even was 
increased. The overexpression of miR-320a in both osteosarcoma cells and hOBs reduced the 
mineralization capacity. Finally, an increased oxidative stress was detected in all cells after 
miR-320a overexpression mainly in osteosarcoma. In conclusion, the overexpression of miR-320a 
increased stress oxidation levels, which could be involved in the reduced osteoblast performance, 
even though the cell viability was only affected in osteosarcoma cells.  
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1. Introduction 
MicroRNAs (miRNAs) are part of cellular processes involved in bone metabolism regulation 
and ageing-related mechanisms [1]. Among bone-related microRNAs, miR-320a was found to be 
elevated in osteoporotic bone [2] and osteoarthritic cartilage tissue [3,4]. This miRNA was also 
detected in serums as a circulating microRNA, and it was proposed as a potential biomarker for 
osteonecrosis of femoral head [5]. Moreover, this miRNA is mainly involved in cancer malignancies 
including osteosarcoma, in which it acts as a tumor suppressor [6–11]. 
In bone tissue, miR-320a is expressed both in primary human osteoblasts (hOBs) and in 
differentiated osteoclasts (hOCs) [12], and it is associated with hOB function [13] by targeting genes 
involved in bone metabolism [14,15]. In a previous study by Wu et al. (2016) [16], a reduced 
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miR-320a expression was observed in several osteosarcoma cell lines compared to in the human 
normal osteoblastic cell line hFOB1.19, but the miRNA-320a effect on cell proliferation was only 
tested in U2OS. Moreover, no other osteoblast functional assessments were evaluated. 
Hence, this miRNA has been extensively studied in osteosarcoma and primary osteoblasts in a 
separated manner, but it has never been tested in both cell types in the same experimental context.  
In this study, in vitro cell assays were performed in order to evaluate the miR-320a effect on 
human osteosarcoma cells compared to that on hOBs. For this purpose, miR-320a was either 
overexpressed or inhibited in MG-63 and U2OS cell lines, and their cell viability, proliferation, and 
oxidative stress were evaluated in comparison to those of hOBs. Moreover, cell functionality by 
measuring matrix mineralization and alkaline phosphatase (ALP) activity was also tested.  
2. Materials and Methods  
2.1. Cell Culture 
hOBs were obtained from knee trabecular bone after prosthesis replacement following the 
protocol described by De-Ugarte et al. [13]. The study was approved by the Clinical Research Ethics 
Committee of Parc de Salut MAR (registry numbers: 2010/3882/I and 2013/5266/I). The study was 
carried out in accordance with the Declaration of Helsinki, and written informed consent was 
obtained from all participants included in the study. Briefly, trabecular bone was dissected in small 
pieces, washed in phosphate-buffered solution (PBS) and placed into a 15 cm-diameter Petri dish in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with a 10% fetal bovine serum (FBS; 
Merck Life Science S.L.U., Madrid, Spain), penicillin and streptomycin (100 UI/mL) (Merck Life 
Science S.L.U., Madrid, Spain), ascorbic acid (100 μg/mL) (Merck Life Science S.L.U., Madrid, Spain), 
and fungisone (0.4%) (Gibco, Fisher Scientific SL; Madrid, Spain ). Explants were incubated at 37 °C 
in a humidified atmosphere of 5% CO2, and the medium was changed once a week until cell 
confluence. All experiments were performed at maximum passage 2. 
In parallel, osteosarcoma cell lines (U2OS and MG-63) were cultured in the same conditions as 
described for hOBs. 
2.2. Cell Transfection 
To evaluate cell viability (MTS assay), cell proliferation (BrdU incorporation), ALP activity, and 
oxidative stress levels (CellRox® Green Reagent assay), 96-well plates with 12,000 cells/well were 
used. For Alizarin red assays, a 24-well plate with 45,000 cells/well was used. 
The transfection protocol was described by De-Ugarte et al. [13]. Briefly, the hsa-miR-320a 
mirVana™ mimic at 100 nM or its inhibitor at 400 nM (Ambion® Life Technologies; Madrid, Spain) 
was transfected using Lipofectamine RNAiMAX (Invitrogen; Carlsbad, USA) according to 
manufacturer instructions. mirVana™ miRNA Mimic Negative Control and miRNA Inhibitor 
Negative Control were used as controls. The mature miR-320a sequence corresponded to 
hsa-miR-320a-3p (5′-AAAAGCTGGGTTGAGAGGGCGA-3′). 
Transfection efficiency was controlled using qPCR and miRIDIAN microRNA Mimic 
Transfection Control with Dy547 as previously described by De-Ugarte et al. [13]. The same 
efficiencies were detected in all tested cell lines (data not shown). 
2.3. miR-320a Quantification by qPCR 
To evaluate the miR-320a expression levels in hOBs, U2OS, and MG-63, total RNA was 
extracted using the miRNeasy Mini Kit (QIAGEN Iberia SL; Madrid, Spain) according to 
manufacturer instructions. Then, 1 μg of total RNA was reverse-transcribed using the miScript II RT 
Kit (QIAGEN Iberia SL; Madrid, Spain). cDNA was assayed in 10 μL qPCR reactions in 384-well 
plates using MiScript SYBR Green PCR Kit according to the protocol. The mature miR-320a sequence 
was used as a forward primer, and the Universal primer was used as a reverse primer. Amplification 
was performed in the QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems; Waltham, 
Massachusetts, USA), and the ExpressionSuite software v.1.0.3 (Life Technologies; Carlsbad, 
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California, USA) was used for the determination of relative quantification (RQ) by 2-ΔΔCt method. 
Global normalization was used to normalize qPCR results. 
2.4. Cell Viability Assay  
Viability was assessed 48 h after miR-320a transfection in hOBs (n = 3), MG-63 (n = 3), and U20S 
(n = 3) using the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega; Madison, 
WI, USA) according to manufacturer instructions. The absorbance was measured at 490 nm with a 
scanning multiwell spectrophotometer Infinite M200 (Tecan).  
2.5. Cell Proliferation Quantification 
Cell Proliferation Elisa, BrdU (Colorimetric) Kit (Roche; Sant Cugat del Vallès, Spain) was used 
to quantify cell proliferation after 48 h of miR-320a or inhibitor transfection in hOBs (n = 3), MG-63 (n 
= 3), and U2OS (n = 3), based on the measurement of BrdU incorporation during DNA synthesis. 
2.6. Osteoblast Mineralization Capacity 
For this test, hOBs and osteosarcoma cell lines were cultured with an osteoblastic medium 
supplemented with 5 mM β-glycerophosphate (Merck Life Science S.L.U., Madrid, Spain); the 
medium was changed three times per week. Osteoblast functionality was analyzed through 
mineralization capacity using Alizarin red staining after 28 days of hOBs culture (n = 6). These cells 
were transfected with both the mimic and inhibitor of miR-320a and the corresponding controls at 
day 1 and day 14 after seeding. In the case of osteosarcoma lines, MG-63 (n = 3) and U2OS (n = 3), 
cells were transfected at day 1 after seeding, and Alizarin red assays were performed after 7 days of 
culture.  
For Alizarin red assays, wells were washed with PBS and fixed with 10% formalin for 10 min at 
room temperature. Then, cells were washed with PBS and stained with a 40 mM Alizarin red 
solution at pH 4.2 (Merck Life Science S.L.U., Madrid, Spain) for 10 min under gentle shaking. After 
that, samples were washed carefully with PBS to remove excess stain, and cell mineralization was 
quantified by dissolving the precipitated Alizarin red assays with a 10% cetylpyridinium chloride 
solution at room temperature during 30 min on gentle shaking. One hundred microliters of the 
stained solutions were measured with a scanning multiwell spectrophotometer using an absorbance 
at 550 nm. 
2.7. ALP Activity Assay 
Osteoblast differentiation was assessed by measuring ALP activity in hOBs (n = 3), MG-63 (n = 
3), and U20S (n = 3) at 48 h after the transfection of miR-320a or its inhibitor using the Alkaline 
Phosphatase Assay Kit (Colorimetric) (Abcam; Cambridge, UK) according to manufacturer 
instructions.  
2.8. Oxidative Stress Evaluation  
CellRox® Green Reagent (10 μM) (Invitrogen; Carlsbad, California, USA) was used to assess the 
oxidative stress levels at 72 h after transfection by following manufacturer instructions. This reagent 
is used for the detection and quantitation of reactive oxygen species (ROS) in live cells. Fluorescence 
levels were evaluated through the LEICA DMIL LED fluorescence microscope using the Leica 
Application Suite (Leica Microsystems). ImageJ software was used for fluorescence comparisons 
among different transfection conditions.  
2.9. Bioinformatic Analyses 
Targets and pathways of miR-320a were predicted using the DIANA-miRPath v3. 0 
(http://snf-515788.vm.okeanos.grnet.gr/#mirnas=hsa-miR-320a&methods=Tarbase&selection=0) , 
which is a computational tool [17] used to identify molecular pathways potentially altered by the 
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miRNA transfection. The platform miRNet (https://www.mirnet.ca/miRNet/home.xhtml) was used 
to construct the interaction network between miR-320a and target genes from data collected from 
four well-annotated databases, i.e., miRTarBase v7.0, TarBase v7.0, miRecords, and miRanda. 
2.10. Statistical Analysis 
The Mann–Whitney U test in the SPSS v.12.0 for Windows was used to compare miR-320a 
mimic and inhibitor with their respective controls. All analyses were two-tailed, and p-values of 
<0.05 were considered significant.  
3. Results 
3.1. miR-320a Levels Quantification 
Basal expression levels of miR-320a were quantified by qPCR in hOB (n = 2), U2OS (n = 2) and 
MG-63 (n = 2) cells. Osteosarcoma cells showed lower miR-320a expression levels compared to hOB 
cells, mainly MG-63 cells (Figure 1). 
 
Figure 1. miR-320a expression levels assessed by qPCR in human osteoblast (hOB), U2OS, and 
MG-63 cells. Data represent the mean ± SD (n = 2). * p < 0.05 for hOB cells. 
3.2. Cell Viability and Proliferation 
The transfection of the miR-320a mimic caused a significant reduction in cell viability in MG-63 
cells (p = 0.046) (Figure 2A). A similar trend was observed in U2OS viability after mimic transfection, 
while an increase of viability (p = 0.045) was observed upon the inhibition of miR-320a. In contrast, 
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Figure 2. Effects of miR-320a on cell viability (A) and proliferation (B) in primary hOBs (n = 3), 
MG-63 (n = 3), and U2OS cells (n = 3) at 48 h post-transfection. Data represent the mean ± SD. * p < 
0.05. 
The overexpression of miR-320a significantly decreased MG-63 and U2OS proliferation (p = 
0.028 and 0.04, respectively), which correlated with the viability results (Figure 2B). In contrast, the 
overexpression of miR-320a (p = 0.045) significantly increased hOB proliferation. In this case, the 
inhibitor transfection did not affect the proliferation in any cell type. 
3.3. ALP Activity 
A decrease of ALP activity was observed after mimic transfection in case of hOBs (p = 0.038). In 
contrast, the effects of ALP activity on MG-63 (p = 0.018) and U2OS cells (p = 0.028) were detected 
after inhibitor transfection, where ALP activity was increased after the inhibition of miR-320a 
(Figure 3). 
 
Figure 3. Effects of miR-320a on alkaline phosphatase activity in primary hOBs (n = 3), MG-63 (n = 
3), and U2OS cells (n = 3) at 48 h post-transfection. Data represent the mean ± SD. * p < 0.05. 
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3.4. Assessment of Cell Mineralization Capacity 
The overexpression of miR-320a reduced matrix mineralization in all cell lines tested, reaching 
significance in hOBs (p = 0.02) and U2OS cells (p = 0.028) (Figure 4). Inhibitor transfection did not 
affect significantly Alizarin red staining. 
 
Figure 4. Effects of miR-320a transfection on the matrix mineralization of hOB and osteosarcoma 
cells. Alizarin red quantification was assayed in hOB cells (n = 6) after 28 days from transfection and 
in MG-63 (n = 3) and U2OS (n = 3) cells after 7 days from transfection. Data represent the mean ± SD. 
* p < 0.05. 
3.5. Cellular Oxidative Stress Measurement 
Osteosarcoma cells had higher ROS levels than hOBs at baseline (transfected with microRNA 
controls) (Figure 5). miR-320a overexpression increased the cell oxidative stress in all cells analyzed. 
Meanwhile, cells transfected with the miR-320a inhibitor showed an opposite effect (Supplementary 
Table S1). Since primary osteoblasts had very low ROS levels at baseline, the effect of the miR-320a 
inhibitor was subtly detected. 
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Figure 5. Effects of miR-320a on cell oxidative stress using CellRox® Green Reagent after 72 h of 
transfection. Images were obtained with the LEICA DMIL LED fluorescence microscope and with 
the Leica Application Suite. Fluorescence levels were quantified using the ImageJ software. 
3.6. Pathway Analysis 
In order to predict the overall effect of the miR-320a regulatory control, the miRPath 3.0 server 
platform was used to identify the cellular pathways potentially affected by this miRNA. Using the 
TarBase v7.0, which is based on experimentally supported miRNA–gene interactions, the most 
significant pathway was the TGF-beta signaling (p = 1.32 × 10-07) with 13 target genes including a 
number of genes of SMAD family, BAMBI, MYC, MAPK1, and TGFBR2. According to miRPath 3.0, 
these genes are involved in osteoblast differentiation, apoptosis, and cell cycle. In addition, the 
miRNet platform (Figure 6) showed pathways in cancer as a significantly enriched function (p = 
0.0209). 
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Figure 6. Network visualization of miR-320a targets enriched in cancer pathways using the miRNet 
server and the KEGG datasource. 
4. Discussion 
miR-320a was described as a tumor suppressor for osteosarcoma [9,11] and involved in 
osteoporotic bone [13], but its effect has never been compared between both cellular contexts. Hence, 
we overexpressed or inhibited miR-320a in two osteosarcoma cell lines, and the miRNA effects on 
these two cells lines were compared to that on primary hOBs. We observed an alteration in 
osteoblast function in all cells tested, involving reduced mineralization and increased oxidative 
stress. However, while viability and proliferation were impaired in osteosarcoma, no effect was 
detected in hOB viability and an increased proliferation was even observed. Interestingly, this 
miRNA is significantly downregulated in osteosarcoma tissues compared to in noncancerous 
tissues [9], and its overexpression significantly inhibited cell proliferation in U2OS [16]. In cervical 
cancer, miR-320a has also been found to be decreased and, similar to our study, to inhibit cell 
proliferation and to induce cell apoptosis [18]. In our study, this miRNA, at the tested doses, 
appeared to reduce the viability of osteosarcoma cells without affecting primary osteoblastic cells, 
suggesting that tumorigenic cells may be more sensitive to miR-320a toxicity. On the contrary, the 
overexpression of miR-320a in hOBs led to increased proliferation but a decreased mineralization 
capability and ALP activity, consistent with a loss of osteoblastic differentiation. It is in accordance 
with the increased levels found in fragility fracture [2], where high miR-320a levels may be involved 
in the osteoporotic phenotype. All these evidences suggested a different effect of miR-320a on 
tumorigenic cells compared to that on primary cells, where on one hand the viability and 
proliferation is reduced and on the other hand cells undergo reduced functionality. It is noteworthy 
that these osteosarcoma cells, which survived after miR-320a transfection, also showed an altered 
functioning in terms of osteoblastic performance. All these results strongly fit with an involvement 
of the TGF-beta signaling pathway predicted by DIANA-miRPath using miR-320a target genes with 
experimental support. The crucial role of TGF-beta signaling pathway in osteoblast proliferation, 
differentiation, and function is well-known [19]. In fact, TGF-beta/BMP signaling was proposed as 
an altered pathway in osteosarcoma cells, according to Yang et al. (2016) [20]. In that study, they 
analyzed transcriptional profiles of osteosarcomas, including two osteosarcoma biopsy specimens, 
two cell lines, and two xenografts derived from patient specimens–one from normal osteoblasts and 
one from mesenchymal stem cells. They concluded that alterations in the signaling axes of IGF-1 and 
TGF-beta, in concert with cell cycle regulators, could be involved in the pathogenic basis of 
osteosarcoma. However, of the 13 miR-320a target genes predicted in the TGF-beta pathway, only 
SMAD5 was validated in an RNA microarray analysis [13] after miR-320a mimic or inhibitor 
transfection (Supplementary Table S2). On the other hand, several genes predicted in cancer 
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pathways have been validated in this microarray (Supplementary Table S3). Since cellular oxidative 
stress can affect cell viability and function, we measured ROS in hOBs and osteosarcoma cells. The 
results showed that the overexpression of miR-320a produced increased ROS levels whereas 
miR-320a inhibition reduced ROS levels. In primary cells, with a normal functioning, minimal ROS 
levels were observed, since they were processed by the cellular antioxidant defense system. The 
increased ROS levels due to miR-320a overexpression could be involved in part in the altered 
functionality [21] provoking cell proliferation increase [22]. The elevated ROS levels of osteosarcoma 
cells, compared to those of untransformed cells, may reflect mitochondrial dysfunction and an 
accelerated metabolism [23]. However, cancer cells are more sensitive than untransformed cells to an 
acute increase in ROS levels. Therefore, an overproduction of intracellular ROS can induce cancer 
cell cycle arrest, senescence, and apoptosis [24]. The increasing levels of ROS due to miR-320a 
overexpression shown in our study would provoke the observed decrease in osteosarcoma cell 
viability without affecting the viability of primary osteoblasts.  
It is noteworthy that microRNA studies performed on established cell lines provide data valid 
only for these cells. Therefore, the results obtained cannot be extrapolated to normal osteoblasts and 
normal bone tissue. 
A limitation of the study is the different effects detected between the mimic and the inhibitor, 
possibly due to the cellular levels of miR-320a, since the inhibitor effect would be conditioned to the 
amount of miRNA present in the cells. Thus, if the amount of miRNA is very small, its action will be 
better observed after mimic transfection rather than after inhibitor transfection. If miRNA 
expression is very high, its action will be better observed after inhibitor transfection rather than after 
mimic transfection. This could explain why in some kinds of cells we observed the mimic effect 
whereas in other cells the effect would be observed through the inhibitor.  
Moreover, the miR-320a effect should be corroborated using xenograft models, through the 
transplantation of MG-63 and U2OS cells, in order to estimate tumor suppressor effects. 
In summary, the overexpression of miR-320a produces an increase in oxidative stress levels and 
a reduced functionality in both hOB and osteosarcoma cells. On the other hand, osteosarcoma cells 
showed a decreased viability and proliferation unlike primary cells that expressed a dedifferentiated 
phenotype. 
Supplementary Materials: The following are available online at www.mdpi.com/2076-3417/10/8/2852/s1, Table 
S1: Measurement of fluorescence levels of CellRox Green Reagent Assay (ImageJ platform); Table S2: Effect of 
miRNA-320a on predicted targeted genes in “TGF-beta signaling pathway”; Table S3: Effect of miRNA-320a on 
predicted targeted genes in “Pathways in cancer”. Only significant genes differentially expressed in microarray 
analysis.  
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